000999.SZ
000999.SZ
CNE0000011K8
CR SANJIU
Loading chart...

Company Profile

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, flu, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, anti-infection, and other treatment areas; Chinese medicine health products; and vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules. It also provides related health services. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. was incorporated in 1999 and is headquartered in Shenzhen, China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources Pharmaceutical Group Limited.

Related stocks

000963.SZ
000963.SZ • China
HD MEDICINE
27.29 CNY
7.16B USD 1Y -34.6%
600085.SS
600085.SS • China
BEIJING TONG REN TANG CO
24.28 CNY
4.98B USD 1Y -29.3%
000423.SZ
000423.SZ • China
DEEJ
46.68 CNY
4.47B USD 1Y -1.3%
688192.SS
688192.SS • China
DIZAL PHARMACEUTICAL CO LTD
59.95 CNY
4.17B USD 1Y -15%
002294.SZ
002294.SZ • China
SALUBRIS
30.93 CNY
5.16B USD 1Y -46.6%
000513.SZ
000513.SZ • China
LIVZON GROUP
30.5 CNY
4.05B USD 1Y -21.4%
2196.HK
2196.HK • China
FOSUN PHARMA
17.87 HKD
6.08B USD 1Y -29.9%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.3% p.a.
Max Drawdown (5Y)
-44.6%
Sharpe Ratio (5Y)
0.16
Beta Factor
-0.02
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -44.6% in the extended horizon.
ende